19.59

0.05% 0.01

Anaptysbio Inc (ANAB)

Overview News Price History Option Chain Financials Discussions Forecast

Anaptysbio Inc stock is traded at $19.59, with a volume of 421.02K. It is up +0.05% in the last 24 hours and up +15.92% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Previous Close:

$19.58

Open:

$19.57

24h Volume:

421.02K

Relative Volume:

0.43

Market Cap:

$622.57M

Revenue:

$17.16M

Net Income/Loss:

$-163.62M

P/E Ratio:

-3.222

EPS:

-6.08

Net Cash Flow:

$-121.61M

1W Performance:

-7.55%

1M Performance:

+15.92%

6M Performance:

-8.07%

1Y Performance:

-25.31%

1-Day Range:

$19.09

$20.04

1-Week Range:

$18.51

$21.52

52-Week Range:

$12.21

$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name

Anaptysbio Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

858-362-6295

Address

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Employee

136

Twitter

@anaptysbio

Next Earnings Date

2024-11-08

Latest SEC Filings

ANAB's Discussions on Twitter

Compare ANAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANAB Anaptysbio Inc	19.59	622.57M	17.16M	-163.62M	-121.61M	-6.08
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight
Apr-16-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Wells Fargo	Overweight
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform
Feb-26-24	Initiated	BTIG Research	Buy
Feb-21-24	Initiated	Stifel	Buy
Feb-16-24	Initiated	Piper Sandler	Overweight
May-22-23	Upgrade	JP Morgan	Underweight → Neutral
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Sep-13-22	Downgrade	Truist	Buy → Hold
Sep-01-22	Initiated	Raymond James	Outperform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy
May-21-21	Initiated	UBS	Neutral
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight
Nov-08-19	Downgrade	Jefferies	Buy → Hold
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Jun-21-19	Downgrade	Credit Suisse	Outperform → Neutral
Jun-21-19	Downgrade	Stifel	Buy → Hold
Dec-20-18	Initiated	H.C. Wainwright	Buy
Nov-21-18	Initiated	JP Morgan	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Apr-04-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-27-18	Reiterated	Stifel	Buy
Mar-06-18	Reiterated	Stifel	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Jan-23-18	Reiterated	Credit Suisse	Outperform
Nov-15-17	Initiated	SunTrust	Buy
Nov-09-17	Initiated	Jefferies	Buy
Oct-11-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform

View All

Anaptysbio Inc Stock (ANAB) Latest News

10:44 AM

(ANAB) Investment Report - news.stocktradersdaily.com

10:44 AM

08:22 AM

Leerink Partnrs Increases Earnings Estimates for AnaptysBio - MarketBeat

08:22 AM

08:14 AM

Fairmount Funds Management LLC Invests $24.05 Million in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

08:14 AM

May 09, 2025

Barclays PLC Has $1.11 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 09, 2025

Invesco Ltd. Sells 28,002 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 09, 2025

Susquehanna Fundamental Investments LLC Invests $593,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 09, 2025

May 08, 2025

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $54.00 at Guggenheim - MarketBeat

May 08, 2025

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

May 08, 2025

Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results - Yahoo Finance

May 08, 2025

May 07, 2025

AnaptysBio (NASDAQ:ANAB) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

May 07, 2025

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly? - simplywall.st

May 07, 2025

AnaptysBio First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 07, 2025

Boxer Capital Management LLC Purchases New Shares in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 07, 2025

Nebula Research & Development LLC Makes New $231,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 07, 2025

AnaptysBio (ANAB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

May 07, 2025

May 06, 2025